Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Adma Biologics (ADMA) over the last 14 years, with Q3 2025 value amounting to $0.15.

  • Adma Biologics' EPS (Basic) changed 0.0% to $0.15 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.88, marking a year-over-year increase of 20344.83%. This contributed to the annual value of $0.85 for FY2024, which is 75236.57% up from last year.
  • As of Q3 2025, Adma Biologics' EPS (Basic) stood at $0.15, which was down 0.0% from $0.14 recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' EPS (Basic) registered a high of $0.48 during Q4 2024, and its lowest value of -$0.16 during Q1 2021.
  • Moreover, its 5-year median value for EPS (Basic) was -$0.03 (2023), whereas its average is $0.01.
  • As far as peak fluctuations go, Adma Biologics' EPS (Basic) crashed by 3333.33% in 2023, and later soared by 121740.92% in 2024.
  • Adma Biologics' EPS (Basic) (Quarter) stood at -$0.07 in 2021, then rose by 14.29% to -$0.06 in 2022, then plummeted by 33.33% to -$0.08 in 2023, then skyrocketed by 700.08% to $0.48 in 2024, then tumbled by 68.75% to $0.15 in 2025.
  • Its EPS (Basic) was $0.15 in Q3 2025, compared to $0.14 in Q2 2025 and $0.11 in Q1 2025.